Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights [Yahoo! Finance]
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Yahoo! Finance
- On track to report topline data from Phase 2 study evaluating CYB004 for the treatment of Generalized Anxiety Disorder ("GAD") in Q1 2026 - Continues to advance Phase 3 studies of CYB003 for the adjunctive treatment of major depressive disorder ("MDD") - -The Company's cash position as at September 30, 2025 after giving effect to the net proceeds of the Registered Direct Offering is US$248 million - Repayment of outstanding convertible debentures to High Trail Special Situations LLC and debt retired in full Company to host conference call and webcast at 8:00 a.m. ET today TORONTO, November 13, 2025 BUSINESS WIRE Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (" Cybin " or the " Company "), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its second quarter ended September 30, 2025, and recent business highli
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Cybin (OTCMKTS:CYBN) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges [Yahoo! Finance]Yahoo! Finance
- Cybin (OTCMKTS:CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $70.00 to $45.00. They now have a "buy" rating on the stock.MarketBeat
- Cybin (OTCMKTS:CYBN) had its price target lowered by analysts at HC Wainwright from $150.00 to $55.00. They now have a "buy" rating on the stock.MarketBeat
- Fibroblast Growth Factors Market Global Forecast Report 2025-2030: Opportunities in Regenerative Medicine, Oncology, and Metabolic Disorders Due to Advances in Molecular Biology, Delivery Technologies [Yahoo! Finance]Yahoo! Finance
CYBN
Earnings
- 11/14/25 - Miss
CYBN
Sec Filings
- 11/26/25 - Form 6-K
- 11/26/25 - Form D
- 11/14/25 - Form SCHEDULE
- CYBN's page on the SEC website